Giant Biogene Holding Co. Ltd. (HK:2367)
:2367
Want to see HK:2367 full AI Analyst Report?
Total Valuation
Giant Biogene Holding Co. Ltd. has a market cap or net worth of HK$28.16B. The enterprise value is HK$21.27B.
Market CapHK$28.16B
Enterprise ValueHK$21.27B
Share Statistics
Giant Biogene Holding Co. Ltd. has 1,061,704,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,061,704,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Giant Biogene Holding Co. Ltd.’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 17.19%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.18
Return on Invested Capital (ROIC)17.19%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee3.14M
Profits Per Employee1.06M
Employee Count1,758
Asset Turnover0.51
Inventory Turnover2.77
Valuation Ratios
The current PE Ratio of Giant Biogene Holding Co. Ltd. is 13.0. Giant Biogene Holding Co. Ltd.’s PEG ratio is -1.28.
PE Ratio13.0
PS Ratio5.73
PB Ratio3.19
Price to Fair Value3.19
Price to FCF21.35
Price to Operating Cash Flow13.29
PEG Ratio-1.28
Income Statement
In the last 12 months, Giant Biogene Holding Co. Ltd. had revenue of 5.52B and earned 1.91B in profits. Earnings per share was 1.83.
Revenue5.52B
Gross Profit4.43B
Operating Income2.12B
Pretax Income2.35B
Net Income1.91B
EBITDA2.19B
Earnings Per Share (EPS)1.83
Cash Flow
In the last 12 months, operating cash flow was 1.88B and capital expenditures -430.78M, giving a free cash flow of 1.45B billion.
Operating Cash Flow1.88B
Free Cash Flow1.45B
Free Cash Flow per Share1.36
Dividends & Yields
Giant Biogene Holding Co. Ltd. pays an annual dividend of HK$1.389, resulting in a dividend yield of 1.84%
Dividend Per ShareHK$1.389
Dividend Yield1.84%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.32
52-Week Price Change-51.21%
50-Day Moving Average27.96
200-Day Moving Average36.16
Relative Strength Index (RSI)45.35
Average Volume (3m)12.22M
Important Dates
Giant Biogene Holding Co. Ltd. upcoming earnings date is Sep 1, 2026, TBA (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateSep 1, 2026
Ex-Dividend Date―
Financial Position
Giant Biogene Holding Co. Ltd. as a current ratio of 11.27, with Debt / Equity ratio of 0.10%
Current Ratio11.27
Quick Ratio10.78
Debt to Market Cap<0.01
Net Debt to EBITDA-2.87
Interest Coverage Ratio7.02K
Taxes
In the past 12 months, Giant Biogene Holding Co. Ltd. has paid 435.64M in taxes.
Income Tax435.64M
Effective Tax Rate0.19
Enterprise Valuation
Giant Biogene Holding Co. Ltd. EV to EBITDA ratio is 11.54, with an EV/FCF ratio of 17.10.
EV to Sales4.59
EV to EBITDA11.54
EV to Free Cash Flow17.10
EV to Operating Cash Flow13.34
Balance Sheet
Giant Biogene Holding Co. Ltd. has HK$8.29B in cash and marketable securities with HK$9.69M in debt, giving a net cash position of HK$8.28B billion.
Cash & Marketable SecuritiesHK$8.29B
Total DebtHK$9.69M
Net CashHK$8.28B
Net Cash Per ShareHK$7.80
Tangible Book Value Per ShareHK$9.38
Margins
Gross margin is 80.34%, with operating margin of 38.43%, and net profit margin of 34.70%.
Gross Margin80.34%
Operating Margin38.43%
Pretax Margin42.59%
Net Profit Margin34.70%
EBITDA Margin39.77%
EBIT Margin38.43%
Analyst Forecast
The average price target for Giant Biogene Holding Co. Ltd. is HK$40.06, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$40.06
Price Target Upside39.28% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-0.47%
EPS Growth Forecast-11.25%